NCT03596970View on ClinicalTrials.gov

Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Liver Transplantation
Interventions
DRUG

TAC withdrawal

Everolimus (RAD001) with MMF and Steroids

DRUG

Everolimus with reduced TAC

Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY